Research and Markets (http://www.researchandmarkets.com/research/6hf8lb/asacol_hd)
has announced the addition of the "Asacol
HD (Ulcerative Colitis) - Forecast and Market Analysis to 2022"
report to their offering.
During the forecast period from 2012-2022, the growth of the UC market
will be driven largely by the entry of Johnson & Johnson's (J&J's)
Simponi and Takeda's Entyvio, which will lead to an increase in the
overall number of patients being treated with biologics in the US, EU,
Japan, and Canada. Another key event affecting the UC market is the
anticipated launch of biosimilars, given that the patent expiry of the
UC blockbusters, Remicade and Humira are set to expire in the US in 2018
and 2016, respectively.
Asacol made a significant impact in the UC market, mstly thanks to
mesalamine's well-known safety profile. In turn, Asacol is considered
the gold standard for mesalamine products in all forms (tablets,
suppositories, enemas). The active ingredient in Asacol, mesalamine,
exerts its function through its anti-inflammatory and immunosuppressive
actions as a COX inhibitor, a blocker of T-cell-activating cytokines, an
adenosine inducer, and an antibody synthesis inhibitor.
Reasons to buy
Key Topics Covered:
1 Table of Contents
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Asacol HD (mesalamine)
For more information visit http://www.researchandmarkets.com/research/6hf8lb/asacol_hd
[ Back To NFVZone's Homepage ]